Stereotactic radiotherapy for liver oligometastatic disease from colorectal cancer

Abstract

Abstract: Liver is the most common site of colorectal cancer metastasis. Patients with oligometastasis may achieve long-term survival after local ablative therapy within the context of improved systemic therapy. Stereotactic radiotherapy (SRT) can deliver radical ablative doses in a small number of fractions precisely. We will discuss the safety and efficacy of SRT for liver oligometastatic disease, compare with other local treatment modality, and how to choose patients who can real benefit from SRT. We represent target volume delineation and dose limitation standard. Finally, we discuss the development of new radiotherapy technology and possibility of SRT to combined with systemic therapy.

Key words: Stereotactic radiotherapy, Colorectal cancer, Liver oligometastatic disease

Lei Junqin, Jin Jing. Stereotactic radiotherapy for liver oligometastatic disease from colorectal cancer[J]. Electronic Journal of Liver Tumor, 2022, 9(4): 26-31.

References

[1] ZHENG R, ZHANG S, ZENG H, et al.Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Center, 2022, 2(1): 1-9.
[2] FONG Y, FORTNER J, SUN R L, et al.Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases[J]. Ann Surg, 1999, 230(3): 309-318.
[3] TOMLINSON J S, JARNAGIN W R, DEMATTEO R P, et al.Actual 10-year survival after resection of colorectal liver metastases defines cure[J]. J Clin Oncol, 2007, 25(29): 4575-4580.
[4] VAN CUTSEM E, CERVANTES A, ADAM R, et al.ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016, 27(8): 1386-1422.
[5] RUERS T, PUNT C, VAN COEVORDEN F, et al.Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase Ⅱ study (EORTC 40004)[J]. Ann Oncol, 2012, 23(10): 2619-2626.
[6] CHANG J Y, SENAN S, PAUL M A, et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Oncol, 2015, 16(6): 630-637.
[7] YUAN Z, TIAN L, WANG P, et al.Comparative research on the efficacy of CyberKnife® and surgical excision for Stage Ⅰ hepatocellular carcinoma[J]. Onco Targets Ther, 2013, 6: 1527-1532.
[8] LEE M T, KIM J J, DINNIWELL R, et al.Phase Ⅰ study of individualized stereotactic body radiotherapy of liver metastases[J]. J Clin Oncol, 2009, 27(10): 1585-1591.
[9] RUSTHOVEN K E, KAVANAGH B D, CARDENES H, et al.Multi-institutional phase Ⅰ/Ⅱ trial of stereotactic body radiation therapy for liver metastases[J]. J Clin Oncol, 2009, 27(10): 1572-1578.
[10] VAN DER POOL A E, MENDEZ ROMERO A, WUNDERINK W, et al. Stereotactic body radiation therapy for colorectal liver metastases[J]. Br J Surg, 2010, 97(3): 377-382.
[11] CHANG DT, SWAMINATH A, KOZAK M, et al.Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis[J]. Cancer, 2011, 117(17): 4060-4069.
[12] STINTZING S, GROTHE A, HENDRICH S, et al.Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases[J]. Acta Oncol, 2013, 52(5): 971-977.
[13] SCORSETTI M, COMITO T, TOZZI A, et al.Final results of a phase Ⅱ trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer[J]. J Cancer Res Clin Oncol, 2015, 141(3): 543-553.
[14] MÉNDEZ ROMERO A, KESKIN-CAMBAY F, VAN OS R M, et al. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy[J]. Rep Pract Oncol Radiother, 2017, 22(2): 126-131.
[15] JOO J H, PARK J H, KIM J C, et al.Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 99(4): 876-883.
[16] MCPARTLIN A, SWAMINATH A, WANG R, et al.Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases[J]. Int J Radiat Oncol Biol Phys, 2017, 99(2): 388-395.
[17] DOI H, UEMOTO K, SUZUKI O, et al.Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer[J]. Oncol Lett, 2017, 14(1): 453-460.
[18] JACKSON W C, TAO Y, MENDIRATTA-LALA M, et al.Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases[J]. Int J Radiat Oncol Biol Phys, 2018, 100(4): 950-958.
[19] YU J, KIM D H, LEE J, et al.Radiofrequency Ablation versus Stereotactic Body Radiation Therapy in the Treatment of Colorectal Cancer Liver Metastases[J]. Cancer Res Treat, 2022, 54(3): 850-859.
[20] WAHL D R, STENMARK M H, TAO Y, et al.Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma[J]. J Clin Oncol, 2016, 34(5): 452-459.
[21] GUCKENBERGER M, LIEVENS Y, BOUMA A B, et al.Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation[J]. Lancet Oncol, 2020, 21(1): e18-e28.
[22] PALMA D A, OLSON R, HARROW S, et al.Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial[J]. Lancet, 2019, 393(10185): 2051-2058.
[23] IYENGAR P, WARDAK Z, GERBER D E, et al.Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial[J]. JAMA Oncol, 2018, 4(1): e173501.
[24] FRANZESE C, COMITO T, TOSKA E, et al.Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy[J]. Radiother Oncol, 2019, 133: 220-226.
[25] PITRODA S P, KHODAREV N N, HUANG L, et al.Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis[J]. Nat Commun, 2018, 9(1): 1793.
[26] OTTAIANO A, CARAGLIA M, DI MAURO A, et al.Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer[J]. Cancers (Basel), 2020, 12(10): 3073.
[27] JETHWA K R, JANG S, MULLIKIN T C, et al.Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer[J]. Radiother Oncol, 2020, 146: 29-36.
[28] SHEIKH S, CHEN H, SAHGAL A, et al.An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer[J]. Radiother Oncol, 2022, 167: 187-194.
[29] TOESCA D A, OSMUNDSON E C, EYBEN R V, et al.Central liver toxicity after SBRT: An expanded analysis and predictive nomogram[J]. Radiother Oncol, 2017, 122(1): 130-136.
[30] DIEZ P, HANNA G G, AITKEN K L, et al.UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy[J]. Clin Oncol (R Coll Radiol), 2022, 34(5): 288-300.
[31] TIMMERMAN R.A Story of Hypofractionation and the Table on the Wall[J]. Int J Radiat Oncol Biol Phys, 2022, 112(1): 4-21.
[32] ARSCOTT W T, THOMPSON R F, YIN L, et al.Stereotactic body proton therapy for liver tumors: Dosimetric advantages and their radiobiological and clinical implications[J]. Phys Imaging Radiat Oncol, 2018, 8: 17-22.
[33] KIM K, YU J I, PARK H C, et al.A phase Ⅱ trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases[J]. Radiother Oncol, 2022, 176: 9-16.
[34] NIERER L, EZE C, DA SILVA MENDES V, et al. Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate[J]. Radiat Oncol, 2022, 17(1): 53.
[35] HERRERA F G, BOURHIS J, COUKOS G.Radiotherapy combination opportunities leveraging immunity for the next oncology practice[J]. CA Cancer J Clin, 2017, 67(1): 65-85.
[36] KWON E D, DRAKE C G, SCHER H I, et al.Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2014, 15(7): 700-712.
[37] LUKE J J, LEMONS J M, KARRISON T G, et al.Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors[J]. J Clin Oncol, 2018, 36(16): 1611-1618.
[38] BAUML J M, MICK R, CIUNCI C, et al.Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial[J]. JAMA Oncol, 2019, 5(9): 1283-1290.
[39] FLOUDAS C S, BRAR G, MABRY-HRONES D, et al.A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer[J]. Clin Colorectal Cancer, 2019, 18(4): e349-e360.
[40] THEELEN W, CHEN D, VERMA V, et al.Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Respir Med, 2021, 9(5): 467-475.
[41] ZHU X, CAO Y, LIU W, et al.Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial[J]. Lancet Oncol, 2021, 22(8): 1093-1102.
[42] MCBRIDE S, SHERMAN E, TSAI C J, et al.Randomized Phase Ⅱ Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma[J]. J Clin Oncol, 2021, 39(1): 30-37.
[43] MAHMOOD U, BANG A, CHEN Y H, et al.A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma[J]. Int J Radiat Oncol Biol Phys, 2021, 109(1): 134-144.
[44] SIVA S, BRESSEL M, WOOD S T, et al.Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial[J]. Eur Urol, 2022, 81(4): 364-372.
[45] MASINI C, IOTTI C, DE GIORGI U, et al.Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase Ⅱ NIVES Study[J]. Eur Urol, 2022, 81(3): 274-282.